Clinical-Trial Outsourcing Is Becoming a Biosecurity Diligence Problem
For years, the biopharma industry treated global clinical-trial geography as an execution question. Companies went where patient recruitment was faster,…
Biotech Buyers Are Paying for Cash-Flow Bridges, Not Just Science
The most revealing biotech deal of the past two days is not really a science-acquisition story at all. It is…
Biopharma Is Paying for Assets That Rewire the Standard of Care
The most interesting biotech deal of the day is not important because of its size alone. It is important because…
Life-Science Tools Are Being Valued Like Therapeutic Platforms
Biotech’s most revealing deal this week did not center on a drug asset, a phase 3 readout, or a late-stage…
Biotech Corridors Are Becoming Products of Their Own
Biotech hubs used to sell themselves with a familiar formula: good universities, venture capital, hospital systems, and a deep pool…
Rare Outbreaks Are Becoming Real-Time Clinical Platforms
One of the more consequential healthcare developments of the past two days has arrived far from the usual biotech spotlight.…
Oncology Is Turning Maintenance Therapy Into Strategy
Drug development stories are often told through breakthroughs at the moment of diagnosis: a new target, a sharper biomarker, a…
The Next Frontier of Healthcare: Why Confidential Computing is the Missing Link in AI-Driven Biotech
We stand at the precipice of a medical revolution. Artificial intelligence is no longer a futuristic concept confined to research…
Clinical-Trial Speed Is Becoming a National Biotech Asset
Biotech policy has spent the last several years talking as if national competitiveness were mainly a question of patents, subsidies,…
Gene Therapy Is Entering Its Durability Audit Era
The latest update from Taysha Gene Therapies is easy to misread as a conventional rare-disease data release. The company announced…
Drug Pricing Is Becoming Trade Policy
Biotech investors are used to thinking about drug pricing as a domestic argument. The traditional battle lines are familiar: governments…